| Literature DB >> 31949461 |
Mohammad Mahdi Shahpouri1, Majid Barekatain2, Mahgol Tavakoli3, Shahin Sanaei1, Vahid Shaygannejad1.
Abstract
BACKGROUND: Multiple sclerosis (MS) can involve cognitive entities, including memory, attention, performance, and information processing. Furthermore, MS causes depression and negatively affects the quality of life (QOL). This study was aimed to assess the efficacy of cognitive rehabilitation on cognitive entities of MS patients.Entities:
Keywords: Attention; cognitive rehabilitation; depression; memory; multiple sclerosis; quality of life
Year: 2019 PMID: 31949461 PMCID: PMC6950338 DOI: 10.4103/jrms.JRMS_124_19
Source DB: PubMed Journal: J Res Med Sci ISSN: 1735-1995 Impact factor: 1.852
Figure 1Consort diagram of the studied population
Demographic and clinical characteristics of the studied population
| Intervention group (%) | Control group (%) | ||
|---|---|---|---|
| Age | 32.21 | 30.46 | 0.449 |
| Gender | |||
| Male | 8 (28.5) | 9 (32.1) | 0.776 |
| Female | 20 (71.4) | 19 (67.8) | |
| Extended disability status score | 2.28 | 1.87 | 0.287 |
| Duration of the disease | 7.46 | 7.07 | 0.639 |
| Relapse rate since the previous year | |||
| No | 18 (64.28) | 19 (67.8) | 0.949 |
| One | 7 (25) | 6 (21.4) | |
| Two | 3 (10.7) | 3 (10.7) | |
| Type of the MS | |||
| Relapsing remitting | 19 (67.8) | 20 (71.4) | 0.943 |
| Primary progressive | 3 (10.7) | 3 (10.7) | |
| Secondary progressive | 6 (21.4) | 5 (17.8) | |
| Drug treatments | |||
| Beta interferon | 19 (67.8) | 21 (75) | 0.822 |
| Fingolimod | 6 (21.4) | 5 (17.8) | |
| Rituximab | 3 (10.7) | 2 (7.1) | |
| Dominant presentation | |||
| Motor symptoms | 13 (46.4) | 10 (35.7) | 0.883 |
| Sensory symptoms | 4 (14.2) | 5 (17.85) | |
| Brainstem symptoms | 6 (21.4) | 6 (21.4) | |
| Sphincteric symptoms | 3 (10.7) | 3 (10.7) | |
| Ocular symptoms | 2 (7.14) | 4 (14.2) |
MS=Multiple sclerosis
Comparison of pretests-posttests derived from patients of two groups
| Variable | Control | Cognitive rehabilitation | Comparing two groups (before treatment) | ||||
|---|---|---|---|---|---|---|---|
| Mean±SD | Mean±SD | ||||||
| Before the intervention | After the intervention | Before the intervention | After the intervention | ||||
| Everyday memory | 109.07±46.39 | 112.57±41.14 | 0.76 | 126.86±49.39 | 92.93±44.29 | <0.001 | 0.994 |
| Prospective and retrospective memory | 42.86±9.70 | 45.57±7.73 | 0.06 | 49.07±9.11 | 36.11±9.76 | <0.001 | 0.568 |
| Digit span memory | 12±2.62 | 11.54±2.41 | 0.23 | 10.14±3.54 | 12±2.95 | <0.001 | 0.705 |
| Physical health | 58.42±12.40 | 56.25±12.09 | 0.38 | 59.46±15.92 | 66.93±15.59 | <0.001 | 0.011 |
| Mental health | 52.18±12.70 | 50.90±15.32 | 0.75 | 50.53±17.09 | 67.77±15.12 | <0.001 | 0.014 |
| Depression | 20.89±6.59 | 20.64±5.69 | 0.83 | 20.8±6.59 | 11±6.86 | <0.001 | 0.062 |
*Paired sample t-test to compare before and after treatment. SD=Standard deviation
Analysis of covariance for evaluating the effectiveness of cognitive rehabilitation on multiple sclerosis patients
| Source | Type III sum of squares | df | Mean square | Significant | |
|---|---|---|---|---|---|
| Intervention | |||||
| Depression | 1010.968 | 1 | 1010.968 | 36.643 | 0.000 |
| PRMQ | 1932.555 | 1 | 1932.555 | 47.286 | 0.000 |
| EMQ | 10959.553 | 1 | 10959.553 | 7.255 | 0.010 |
| Digit span test | 36.195 | 1 | 36.195 | 11.944 | 0.001 |
| Physical health | 1285.000 | 1 | 1285.000 | 3.631 | 0.063 |
| Mental health | 4695.908 | 1 | 4695.908 | 3.267 | 0.077 |
| Error | |||||
| Depression | 1324.309 | 48 | 27.590 | ||
| PRMQ | 1961.730 | 48 | 40.869 | ||
| EMQ | 72513.120 | 48 | 1510.690 | ||
| Digit span test | 145.457 | 48 | 3.030 | ||
| Physical health | 16987.956 | 48 | 353.916 | ||
| Mental health | 68988.040 | 48 | 1437.251 |
PRMQ=Prospective and Retrospective Memory Questionnaire; EMQ=Everyday Memory Questionnaire